## Type 2 Diabetes Medications Marketed in Canada (v. March 4, 2024)

Generic name, brand name, available strengths	Health Canada adult starting dose (range) <sup>1</sup> See Canadian monographs for titration details	Approximate annual cost <sup>2</sup> BC PharmaCare coverage	
METFORMIN			
metformin GLUCOPHAGE, generics 500, 850 mg	500 mg PO BID; 850 mg PO once daily (1500-2550 mg/day) <sup>3</sup>	\$20-40	Regular benefit
metformin ER GLUMETZA, generics 500, 1000 mg	1000 mg ER PO once daily (1000-2000 mg/day)	\$465-\$930	Non-benefit
SULFONYLUREAS (SU)			
glyburide generics 2.5, 5 mg	2.5 mg PO once daily > 60 years 5 mg PO once daily < 60 years (2.5-20 mg/day)	\$15-\$90	Regular benefit
gliclazide generics 80 mg	80 mg PO BID (80-320 mg/day)	\$75-\$150	Limited Coverage
gliclazide MR DIAMICRON MR, generics 30, 60 mg	30 mg MR PO once daily (30-120 mg/day)	\$40-\$50	Plan W regular benefit*
glimepiride generics 1, 2, 4 mg	1 mg PO once daily (1-8 mg/day)	\$325-\$830	Non-benefit

SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS (SGLT2i)			
dapagliflozin FORXIGA, generics 5, 10 mg	5 mg PO once daily (5-10 mg/day)	\$270	Regular benefit
+ metformin XIGDUO, generics 5+850/1000 mg	1 tab PO BID	\$705-\$760	Non-benefit
empagliflozin JARDIANCE 10, 25 mg	10 mg PO once daily (10-25 mg/day)	\$1090	Limited Coverage
+ metformin SYNJARDY 5+500/850/1000 mg, 12.5+500/850/1000 mg	1 tab PO BID	\$1125	
canagliflozin INVOKANA 100, 300 mg	100 mg PO once daily (100-300 mg/day)	\$1140	
+ metformin INVOKAMET 50+500/1000 mg, 150+500/1000 mg	1 tab PO BID	\$1310	Non-benefit

GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP1)			
semaglutide OZEMPIC 3 mL multidose prefilled pens (2 mg/pen: 0.25, 0.5 mg/dose and 4 mg/pen: 1 mg/dose) 2 mg/dose prefilled pens: not available	0.25 mg subcut once weekly for 4 weeks, then $\uparrow$ to 0.5 mg/week (may titrate every 4 weeks to a maximum dose of 2 mg/week)	\$2960	Limited Coverage 2 mg dose: non-benefit
semaglutide RYBELSUS 3, 7, 14 mg tablets	3 mg orally once daily on an empty stomach for 30 days, then $\uparrow$ to 7 mg/day (may $\uparrow$ to 14 mg/day after subsequent 30 days)	\$2840	Non-benefit
<b>dulaglutide</b> TRULICITY 0.5 mL single dose prefilled pens (0.75, 1.5 mg/dose) <i>3 mg/dose and 4.5 mg/dose prefilled pens: not available</i>	0.75 mg subcut once weekly (may ↑ to 1.5 mg/week after 1 week, then may titrate every 4 weeks to a maximum dose of 4.5 mg/week)	\$3040	Non-benefit
<b>liraglutide</b> VICTOZA: 3 mL multidose prefilled pens (18 mg/pen: 0.6, 1.2, 1.8 mg/dose)	0.6 mg subcut once daily for 1 week, then $\uparrow$ to 1.2 mg/day (may $\uparrow$ to 1.8 mg/day after 1 week)	\$3955	Non-benefit

## GLUCAGON-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) & GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP1)

tirzepatide MOUNJARO 0.5 mL single-dose vials (2.5, 5, 7.5, 10, 12.5, 15 mg/dose)	2.5 mg subcut once weekly for 4 weeks, then ↑ to 5 mg/week (may titrate every 4 weeks in 2.5 mg increments to a maximum dose of 15 mg/week)	\$4325	Non-benefit	
---	---	--------	-------------	--

BASAL INSULIN + GLP1 AGONIST FIXED-DOSE COMBINATIONS <sup>†</sup>			
insulin degludec + liraglutide XULTOPHY 3 mL multidose prefilled pens (100 units/mL + 3.6 mg/mL: 1 unit = 1 unit of degludec + 0.036 mg liraglutide)	basal insulin or GLP1 naïve: 10 units subcut once daily currently on basal insulin or GLP1: 16 units subcut once daily (maximum 50 units degludec + 1.8 mg liraglutide subcut/day) <sup>†</sup>	\$4060	Non-benefit
<b>insulin glargine + lixisenatide</b> SOLIQUA 3 mL multidose prefilled pens (SoloSTAR) (100 units/mL + 33 mcg/mL: 1 unit = 1 unit of glargine + 0.33 mcg lixisenatide)	do not exceed lixisenatide 10 mcg subcut/day initially (15-60 units insulin glargine + 5-20 mcg lixisenatide subcut/day within 1 hour prior to first meal) <sup>†</sup>	\$3130	Non-benefit

BID twice a day; ER extended-release; MR modified-release; subcut subcutaneous; XR extended-release; TID three times a day; <sup>1</sup>Heath Canada Drug Product Database; <sup>2</sup>Cost range: includes initial to maximum dose without mark-up or professional fee rounded to the nearest \$5 (GLP1a cost is for the maximum/maintenance dose) calculated from McKesson Canada March 1, 2024; <sup>3</sup>US Food and Drug Administration Glucophage (metformin); \*Plan W exceptions: see FNHA Summary of Diabetes Drugs; †Basal insulin + GLP1 agonist combinations: see Health Canada Drug Product Monographs for complex dosing instructions which take into account prior basal insulin dose

This document has been compiled for the British Columbia Ministry of Health's Pharmaceutical, Laboratory and Blood Services Division. The information contained in this document is intended for educational purposes only and is not intended as a substitute for the advice or professional judgment of a health care professional. The information in this document is provided without any express or implied warranty regarding its content, and no party involved with the preparation of this document is responsible for any errors or omissions that may be contained herein, nor is any party involved with the preparation of this document is document will imply acknowledgement of this disclaimer and release the Province of British Columbia, its employees, agents and any party involved in the preparation of this document from any and all liability. Copyright © 2024, Province of British Columbia. All rights reserved.

BC Provincial Academic Detailing Service Email: PAD@gov.bc.ca Web: www.bcpad.ca

## Type 2 Diabetes Medications Marketed in Canada (v. March 4, 2024)

Generic name, brand name, available strengths	Health Canada adult starting dose (range) <sup>1</sup> See Canadian monographs for titration details	Approximate annual cost <sup>2</sup> BC PharmaCare coverage	
DIPEPTIDYL PEPTIDASE 4 INHIBITORS (DPP4i)			
linagliptin TRAJENTA 5 mg	5 mg PO once daily (5 mg/day)	\$940	Limited Coverage
+ metformin JENTADUETO 2.5+500/850/1000 mg	1 tab PO BID	\$990	- Limited Coverage
saxagliptin ONGLYZA, generics 2.5, 5 mg	5 mg PO once daily (2.5-5 mg/day)	\$500-\$600	
+ metformin KOMBOGLYZE 2.5+500/850/1000 mg	1 tab PO BID	\$1065	Limited Coverage
alogliptin NESINA 6.25, 12.5, 25 mg	25 mg PO once daily (6.25-25 mg/day)	\$870	New here of t
+ metformin KAZANO 12.5+1000 mg	1 tab PO BID	\$945	Non-benefit
sitagliptin JANUVIA, generics 25, 50, 100 mg	100 mg PO once daily (25-100 mg/day)	\$1100	
+ metformin JANUMET, generics 50+500/850/1000 mg	1 tab PO BID	\$1195	- Non-benefit
+ metformin XR JANUMET XR, generics 50+500/1000 mg, 100+1000 mg	50+500/1000 mg: 2 XR tabs PO once daily 100+1000 mg: 1 XR tab PO once daily	\$550-\$1105	
MEGLITINIDE ANALOGUE			
repaglinide GLUCONORM, generics 0.5, 1, 2 mg	0.5 mg PO TID (1.5-16 mg/day)	\$250-\$770	Non-benefit
THIAZOLIDINEDIONES (TZD)			
pioglitazone generics 15, 30, 45 mg	15 mg PO once daily (15-45 mg/day)	\$185-\$390	Limited Coverage
rosiglitazone generics 2, 4, 8 mg	4 mg PO once daily or 2 mg PO BID (4-8 mg/day)	\$760-\$1085	Non-benefit
ALPHA-GLUCOSIDASE INHIBITOR			·
acarbose generics 50, 100 mg	50 mg PO once daily (150-300 mg/day)	\$90-\$375	Non-benefit
PO oral; BID twice a day; XR extended-release; TID three times a day; <sup>1</sup> Heath Ca	anada Drug Product Database; <sup>2</sup> Cost range: includes initial to maximum	dose rounded to t	he nearest \$5 without ma

up or professional fee calculated from McKesson Canada March 1, 2024

Generic name, brand name, available strengths, dosage forms <sup>1</sup>		Approximate cost per 100 units BC PharmaCare coverage <sup>2</sup>	
BASAL INSULINS			
insulin NPH 100 units/mL HUMULIN N, NOVOLIN ge NPH vial, cartridges, prefilled pens (KwikPen)	< \$5	Regular benefit	
insulin glargine biosimilar 100 units/mL BASAGLAR cartridges, prefilled pens (KwikPen)	< \$10 Limited Coverage	Limited Coverage	
insulin glargine biosimilar 100 units/mL SEMGLEE prefilled pens	< \$5	Plan W regular benefit	
insulin glargine 100 units/mL LANTUS vial, cartridges, prefilled pens (SoloSTAR)	< \$10	Non-benefit	
insulin glargine 300 units/mL TOUJEO prefilled pens (SoloSTAR, DoubleSTAR)	< \$10	Non-benefit	
insulin detemir 100 units/mL LEVEMIR cartridges	< \$10	Limited Coverage	
insulin degludec 100 units/mL, 200 units/mL TRESIBA cartridges, prefilled pens (FlexTouch)	< \$10	Non-benefit	
BOLUS (PRANDIAL) INSULINS			
insulin regular 100 units/mL HUMULIN R, NOVOLIN ge Toronto vial, cartridges, prefilled pens (KwikPen non-benefit)	< \$5	Regular benefit	
insulin regular 500 units/mL ENTUZITY basal + bolus activity, prefilled pens (KwikPen)	< \$5	Regular benefit	
insulin aspart biosimilar 100 units/mL TRURAPI, KIRSTY vial, cartridges, prefilled pens (SoloSTAR), prefilled pens	s < \$5	Regular benefit	
insulin aspart 100 units/mL NOVORAPID vial, cartridges	< \$5	Non-benefit**	
insulin aspart 100 units/mL FIASP vial, cartridges, prefilled pens (FlexTouch)	< \$5	Non-benefit	
insulin glulisine 100 units/mL APIDRA vial, cartridges, prefilled pens (SoloSTAR)	< \$5	Regular benefit	
insulin lispro biosimilar 100 units/mL ADMELOG vial, cartridges, prefilled pens (SoloSTAR)	< \$5	Regular benefit	
insulin lispro 100 units/mL HUMALOG vial, cartridges, prefilled pens (KwikPen, Junior KwikPen)	< \$5	Non-benefit**	
insulin lispro 200 units/mL HUMALOG prefilled pens (KwikPen)	< \$5	Non-benefit	
BASAL + BOLUS INSULINS			
insulin regular + NPH 100 units/mL HUMULIN 30/70, NOVOLIN ge 30/70, 40/60, 50/50 vial, cartridges	< \$5	Regular benefit	
insulin aspart + aspart protamine 100 units/mL NOVOMIX 30 cartridges	< \$5	Non-benefit	
insulin lispro + lispro protamine 100 units/mL HUMALOG Mix25, Mix50 cartridges, prefilled pens (KwikPen)	< \$5	Non-benefit	
IPH neutral protamine Hagedorn; 1Heath Canada Drug Product Database; 2Cost per 100 units without mark-up calculated from McKesson Canada Ma	rch 1, 2024 (insul	in is a Schedule II Professior	

**NPH** neutral protamine Hagedorn; <sup>1</sup>Heath Canada Drug Product Database; <sup>2</sup>Cost per 100 units without mark-up calculated from McKesson Canada March 1, 2024 (insulin is a Schedule II Professional Service Area retail drug and does not require a prescription); \*Plan W exceptions: see FNHA Summary of Diabetes Drugs; \*\*for updated insulin coverage information and exceptions: see BC PharmaCare Biosimilars Initiative

This document has been compiled for the British Columbia Ministry of Health's Pharmaceutical, Laboratory and Blood Services Division. The information contained in this document is intended for educational purposes only and is not intended as a substitute for the advice or professional judgment of a health care professional. The information in this document is provided without any express or implied warranty regarding its content, and no party involved with the preparation of this document is responsible for any errors or omissions that may be contained herein, nor is any party involved with the preparation of this document responsible for the result obtained from the use of information in this document will imply acknowledgement of this discliner and release the Province of British Columbia, its employees, agents and any party involved in the preparation of this document from any and all liability. Copyright © 2024, Province of British Columbia. All rights reserved.

BC Provincial Academic Detailing Service Email: PAD@gov.bc.ca Web: www.bcpad.ca